AU2009229372C1 - Use and composition for treating dementia - Google Patents

Use and composition for treating dementia Download PDF

Info

Publication number
AU2009229372C1
AU2009229372C1 AU2009229372A AU2009229372A AU2009229372C1 AU 2009229372 C1 AU2009229372 C1 AU 2009229372C1 AU 2009229372 A AU2009229372 A AU 2009229372A AU 2009229372 A AU2009229372 A AU 2009229372A AU 2009229372 C1 AU2009229372 C1 AU 2009229372C1
Authority
AU
Australia
Prior art keywords
achei
group
pharmaceutically acceptable
nspacha
rivastigmine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009229372A
Other languages
English (en)
Other versions
AU2009229372A1 (en
AU2009229372B2 (en
Inventor
Thomas N. Chase
Kathleen E. Clarence-Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chase Pharmaceuticals Corp
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009229372(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of AU2009229372A1 publication Critical patent/AU2009229372A1/en
Application granted granted Critical
Publication of AU2009229372B2 publication Critical patent/AU2009229372B2/en
Priority to AU2014277685A priority Critical patent/AU2014277685C1/en
Priority to AU2016231489A priority patent/AU2016231489B2/en
Priority to AU2016231493A priority patent/AU2016231493B2/en
Publication of AU2009229372C1 publication Critical patent/AU2009229372C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009229372A 2008-03-27 2009-03-17 Use and composition for treating dementia Ceased AU2009229372C1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2014277685A AU2014277685C1 (en) 2008-03-27 2014-12-16 Composition for treating dementia
AU2016231489A AU2016231489B2 (en) 2008-03-27 2016-09-20 Composition for treating dementia
AU2016231493A AU2016231493B2 (en) 2008-03-27 2016-09-20 Composition for treating dementia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08005750.8 2008-03-27
EP08005750 2008-03-27
PCT/US2009/001662 WO2009120277A1 (en) 2008-03-27 2009-03-17 Use and composition for treating dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014277685A Division AU2014277685C1 (en) 2008-03-27 2014-12-16 Composition for treating dementia

Publications (3)

Publication Number Publication Date
AU2009229372A1 AU2009229372A1 (en) 2009-10-01
AU2009229372B2 AU2009229372B2 (en) 2014-09-25
AU2009229372C1 true AU2009229372C1 (en) 2017-02-02

Family

ID=39535697

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009229372A Ceased AU2009229372C1 (en) 2008-03-27 2009-03-17 Use and composition for treating dementia

Country Status (10)

Country Link
US (5) US8404701B2 (enExample)
EP (3) EP4088717A1 (enExample)
JP (3) JP5647099B2 (enExample)
AU (1) AU2009229372C1 (enExample)
CA (1) CA2718411C (enExample)
DK (1) DK2271218T3 (enExample)
ES (1) ES2634421T3 (enExample)
MX (3) MX347901B (enExample)
PL (1) PL2271218T3 (enExample)
WO (1) WO2009120277A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
EP4088717A1 (en) * 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
ES2746480T3 (es) 2009-09-18 2020-03-06 Chase Pharmaceuticals Corp Combinación para tratar demencia de tipo Alzheimer
JP2011213606A (ja) * 2010-03-31 2011-10-27 Sawai Pharmaceutical Co Ltd ドネペジルを含有する固形製剤の製造方法
JP2011213695A (ja) * 2010-04-02 2011-10-27 Taisho Pharm Ind Ltd ドネペジル塩酸塩含有口腔内速崩壊錠
KR20200065113A (ko) 2012-09-05 2020-06-08 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
US10149828B2 (en) * 2015-01-09 2018-12-11 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
US10596139B2 (en) 2015-03-06 2020-03-24 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
EP3265466A4 (en) * 2015-03-06 2018-12-26 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
US10307409B2 (en) * 2015-03-06 2019-06-04 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
WO2016204998A1 (en) 2015-06-15 2016-12-22 Qaam Pharmaceuticals, Llc Glycopyrronium fatty acid salts and methods of making same
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
US10479706B2 (en) * 2016-06-03 2019-11-19 Katz Water Tech, Llc Apparatus, method and system for desalinating water
TW201821068A (zh) * 2016-10-28 2018-06-16 美商查斯製藥公司 美金剛胺(memantine)組合及用途
BR112020021173A2 (pt) * 2018-04-17 2021-01-19 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico para a administração transdérmica de solifenacina
IL281809B (en) 2018-09-28 2022-09-01 Karuna Therapeutics Inc Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors
US20240024261A1 (en) * 2020-09-21 2024-01-25 Dr. Raymond Lab Inc Pharmaceutical composition for improving cognitive ability or enhancing memory
EP4251608A4 (en) * 2020-11-26 2025-02-12 Rezubio Pharmaceuticals Co., Ltd ANTICHOLINERGIC AGENTS
US12109202B2 (en) 2021-01-29 2024-10-08 Qaam Pharmaceuticals, Llc Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065176A1 (en) * 2003-09-22 2005-03-24 Field Mark John Combinations
WO2008033299A2 (en) * 2006-09-12 2008-03-20 Adolor Corporation Use of n-containing spirocompounds for the enhancement of cognitive function

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB795758A (en) 1955-08-22 1958-05-28 Pfizer & Co C Amino esters and the preparation thereof
US3480626A (en) 1967-05-18 1969-11-25 Chem Fab Dr R Pfleger Certain azoniaspironortropine derivatives
GB1204580A (en) 1968-10-05 1970-09-09 Aspro Nicholas Ltd Pharmaceutical dosage forms
US3576388A (en) 1968-12-05 1971-04-27 Stauffer Wacker Silicone Corp Electrical cable
DD106643A1 (enExample) 1973-07-12 1974-06-20
US4965074A (en) 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US4798841A (en) 1987-03-31 1989-01-17 Warner-Lambert Company Tetrahydropyridine oxime cholinergic agents and method of treatment
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
US4937239A (en) 1989-02-13 1990-06-26 Warner-Lambert Company Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
GB9612710D0 (en) 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
ES2255170T3 (es) 1997-07-09 2006-06-16 Axonyx Inhibidores de butirilcolinesterasa altamente selectivos para el tratamiento y diagnostico de demencias y de la enfermedad de alzheimer.
EP0976404A3 (en) 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
CA2310926C (en) 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
WO2002072093A2 (en) * 2001-02-08 2002-09-19 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7427280B2 (en) * 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
US6974820B2 (en) 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium
CN1520818A (zh) 2003-02-09 2004-08-18 ɽ����Ҷ��Ȼҩ���о��������޹�˾ 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8299062B2 (en) 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
CA2552558A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
JP2007523122A (ja) 2004-02-20 2007-08-16 ノバルティス アクチエンゲゼルシャフト 神経変性障害および認知障害の処置のためのｄｐｐ−ｉｖ阻害剤
AR051950A1 (es) 2004-11-10 2007-02-21 Osmotica Pharmaceutical Argent Comprimido multicapa con capas que se separan
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
US20070004766A1 (en) 2005-07-01 2007-01-04 Aberg A K G Methods for relaxation of smooth muscle contractions using Trospium
US20070224259A1 (en) 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
PT1933809E (pt) 2005-10-11 2012-04-26 Yissum Res Dev Co Composições para administração por via nasal
CA2649396A1 (en) * 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
US20080090808A1 (en) 2006-10-17 2008-04-17 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
US8097633B2 (en) * 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
EP4088717A1 (en) 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
ES2746480T3 (es) * 2009-09-18 2020-03-06 Chase Pharmaceuticals Corp Combinación para tratar demencia de tipo Alzheimer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065176A1 (en) * 2003-09-22 2005-03-24 Field Mark John Combinations
WO2008033299A2 (en) * 2006-09-12 2008-03-20 Adolor Corporation Use of n-containing spirocompounds for the enhancement of cognitive function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FABER et al., 'Enhancing the Tolerability of Tacrine With Propantheline', The American Journal of Psychiatry, 1999, Vol. 156, No. 1, page 156. *

Also Published As

Publication number Publication date
MX347901B (es) 2017-05-18
CA2718411A1 (en) 2009-10-01
WO2009120277A1 (en) 2009-10-01
US20150224096A1 (en) 2015-08-13
JP2011518776A (ja) 2011-06-30
MX344177B (es) 2016-12-08
EP3178477A1 (en) 2017-06-14
JP2016179980A (ja) 2016-10-13
EP2271218B1 (en) 2017-05-24
US20140275036A1 (en) 2014-09-18
JP6427522B2 (ja) 2018-11-21
ES2634421T3 (es) 2017-09-27
CA2718411C (en) 2016-02-16
US20110021503A1 (en) 2011-01-27
US8404701B2 (en) 2013-03-26
DK2271218T3 (en) 2017-09-11
JP2014114295A (ja) 2014-06-26
US9044472B2 (en) 2015-06-02
EP2271218A4 (en) 2011-05-18
EP2271218A1 (en) 2011-01-12
PL2271218T3 (pl) 2017-10-31
AU2009229372A1 (en) 2009-10-01
AU2009229372B2 (en) 2014-09-25
US20190091214A1 (en) 2019-03-28
JP5647099B2 (ja) 2014-12-24
US20130158012A1 (en) 2013-06-20
EP4088717A1 (en) 2022-11-16
MX2010010460A (es) 2010-12-15

Similar Documents

Publication Publication Date Title
CA2718411C (en) Use and composition for treating dementia
US9913836B2 (en) Anticholinergic neuroprotective composition and methods
US9278092B2 (en) Method and composition for treating alzheimer-type dementia
AU2016231493B2 (en) Composition for treating dementia
AU2016231489B2 (en) Composition for treating dementia
AU2014277685B2 (en) Composition for treating dementia
AU2018201519A1 (en) Method and composition for treating Alzheimer-type dementia
HK1239557A1 (en) Combination of a nspacha (peripheral anticholinergic agent) like solifenacin and an achei (acetyl choline esterase inhibitor) like donepezil for treating dementia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 OCT 2016

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 OCT 2016

MK14 Patent ceased section 143(a) (annual fees not paid) or expired